TWI895248B - 針對金黃色葡萄球菌白血球毒素的抗體 - Google Patents
針對金黃色葡萄球菌白血球毒素的抗體Info
- Publication number
- TWI895248B TWI895248B TW108136342A TW108136342A TWI895248B TW I895248 B TWI895248 B TW I895248B TW 108136342 A TW108136342 A TW 108136342A TW 108136342 A TW108136342 A TW 108136342A TW I895248 B TWI895248 B TW I895248B
- Authority
- TW
- Taiwan
- Prior art keywords
- antibody
- antigen
- binding fragment
- staphylococcus aureus
- infection
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Gram-positive bacteria
- C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56938—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862743501P | 2018-10-09 | 2018-10-09 | |
| US62/743,501 | 2018-10-09 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202028232A TW202028232A (zh) | 2020-08-01 |
| TWI895248B true TWI895248B (zh) | 2025-09-01 |
Family
ID=68393067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW108136342A TWI895248B (zh) | 2018-10-09 | 2019-10-08 | 針對金黃色葡萄球菌白血球毒素的抗體 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11059884B2 (https=) |
| EP (1) | EP3864040A1 (https=) |
| JP (1) | JP7459075B2 (https=) |
| KR (1) | KR20210080411A (https=) |
| CN (1) | CN113015745B (https=) |
| AU (1) | AU2019359207A1 (https=) |
| BR (1) | BR112021006704A2 (https=) |
| CA (1) | CA3115765A1 (https=) |
| MX (1) | MX2021004114A (https=) |
| TW (1) | TWI895248B (https=) |
| WO (1) | WO2020076790A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX375324B (es) * | 2012-11-06 | 2025-03-06 | Medimmune Llc | Anticuerpos contra determinantes de la superficie de s. aureus. |
| TWI902669B (zh) | 2018-07-24 | 2025-11-01 | 美商麥迪紐有限責任公司 | 抗金黃色葡萄球菌凝集因子a(clfa)之抗體 |
| MX2021004114A (es) | 2018-10-09 | 2021-07-16 | Medimmune Llc | Anticuerpos dirigidos contra leucotoxinas de staphylococcus aureus. |
| CN113164602A (zh) | 2018-10-09 | 2021-07-23 | 免疫医疗有限责任公司 | 抗金黄色葡萄球菌抗体的组合 |
| CN113811544A (zh) | 2019-03-13 | 2021-12-17 | 免疫医疗有限责任公司 | 减少定殖患者中的金黄色葡萄球菌感染 |
| CN113583119B (zh) * | 2021-07-07 | 2023-05-02 | 西北农林科技大学 | 抗金黄色葡萄球菌的纳米抗体Nb56、应用及试剂盒 |
| CN113493510A (zh) * | 2021-07-07 | 2021-10-12 | 上海交通大学 | 一种牛源抗金黄色葡萄球菌LukD毒力因子的单链抗体及其制备和应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015055814A1 (en) * | 2013-10-17 | 2015-04-23 | Arsanis Biosciences Gmbh | Cross-reactive staphylococcus aureus antibody sequences |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
| BRPI0807952A2 (pt) | 2007-02-20 | 2014-06-10 | Anaptysbio Inc | Sistemas de hipermutação somática |
| CN104119438A (zh) | 2009-01-29 | 2014-10-29 | 米迪缪尼有限公司 | 延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用 |
| RU2677140C1 (ru) * | 2010-05-05 | 2019-01-15 | Нью-Йорк Юниверсити | Лейкоцидины staphylococcus aureus, терапевтические композиции и их применение |
| EP3470526A3 (en) | 2011-02-08 | 2019-07-17 | Medimmune, LLC | Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use |
| US9845348B2 (en) | 2012-11-06 | 2017-12-19 | Medimmune, Llc | Methods of treating S. aureus-associated diseases |
| MX375324B (es) | 2012-11-06 | 2025-03-06 | Medimmune Llc | Anticuerpos contra determinantes de la superficie de s. aureus. |
| EP3142700B1 (en) | 2014-05-16 | 2021-03-03 | Medimmune, LLC | Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties |
| TWI719938B (zh) | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
| MX2017012775A (es) | 2015-04-17 | 2019-04-29 | Arsanis Biosciences Gmbh | Preparacion combinatoria de anticuerpos anti-staphylococcus aureus. |
| US20190077851A1 (en) | 2015-10-30 | 2019-03-14 | Bruno Francois | Methods of using anti-alpha toxin antibody |
| TWI902669B (zh) | 2018-07-24 | 2025-11-01 | 美商麥迪紐有限責任公司 | 抗金黃色葡萄球菌凝集因子a(clfa)之抗體 |
| CN113164602A (zh) | 2018-10-09 | 2021-07-23 | 免疫医疗有限责任公司 | 抗金黄色葡萄球菌抗体的组合 |
| MX2021004114A (es) | 2018-10-09 | 2021-07-16 | Medimmune Llc | Anticuerpos dirigidos contra leucotoxinas de staphylococcus aureus. |
-
2019
- 2019-10-08 MX MX2021004114A patent/MX2021004114A/es unknown
- 2019-10-08 WO PCT/US2019/055144 patent/WO2020076790A1/en not_active Ceased
- 2019-10-08 JP JP2021519609A patent/JP7459075B2/ja active Active
- 2019-10-08 TW TW108136342A patent/TWI895248B/zh active
- 2019-10-08 EP EP19795711.1A patent/EP3864040A1/en active Pending
- 2019-10-08 CN CN201980074188.5A patent/CN113015745B/zh active Active
- 2019-10-08 AU AU2019359207A patent/AU2019359207A1/en active Pending
- 2019-10-08 CA CA3115765A patent/CA3115765A1/en active Pending
- 2019-10-08 BR BR112021006704-3A patent/BR112021006704A2/pt unknown
- 2019-10-08 US US16/596,445 patent/US11059884B2/en active Active
- 2019-10-08 KR KR1020217013374A patent/KR20210080411A/ko active Pending
-
2021
- 2021-06-07 US US17/340,622 patent/US11578119B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015055814A1 (en) * | 2013-10-17 | 2015-04-23 | Arsanis Biosciences Gmbh | Cross-reactive staphylococcus aureus antibody sequences |
Also Published As
| Publication number | Publication date |
|---|---|
| US11578119B2 (en) | 2023-02-14 |
| KR20210080411A (ko) | 2021-06-30 |
| JP7459075B2 (ja) | 2024-04-01 |
| EP3864040A1 (en) | 2021-08-18 |
| US20200109190A1 (en) | 2020-04-09 |
| CN113015745B (zh) | 2025-02-11 |
| WO2020076790A1 (en) | 2020-04-16 |
| TW202028232A (zh) | 2020-08-01 |
| US20210363229A1 (en) | 2021-11-25 |
| BR112021006704A2 (pt) | 2021-08-10 |
| CN113015745A (zh) | 2021-06-22 |
| AU2019359207A1 (en) | 2021-05-20 |
| CA3115765A1 (en) | 2020-04-16 |
| JP2022512646A (ja) | 2022-02-07 |
| US11059884B2 (en) | 2021-07-13 |
| MX2021004114A (es) | 2021-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI895248B (zh) | 針對金黃色葡萄球菌白血球毒素的抗體 | |
| EP3277321B1 (en) | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) | |
| US20240352098A1 (en) | ANTIBODY DIRECTED AGAINST S. AUREUS CLUMPING FACTOR A (ClfA) | |
| US11168133B2 (en) | Combinations of anti-Staphylococcus aureus antibodies | |
| RU2770209C2 (ru) | Терапевтические антитела против лиганда cd40 | |
| WO2014028748A1 (en) | Interleukin 2 antibodies and antibody complexes | |
| JP2023113655A (ja) | 小児の障害を処置する方法 | |
| WO2021186398A1 (en) | Anti-klebsiella pneumoniae antibodies and uses thereof | |
| RU2805969C2 (ru) | Антитела, направленные против лейкотоксинов staphylococcus aureus | |
| US20240124606A1 (en) | Anti-cd73 monoclonal antibodies | |
| RU2818805C2 (ru) | АНТИТЕЛО, НАПРАВЛЕННОЕ ПРОТИВ ФАКТОРА СЛИПАНИЯ А (ClfA) S. aureus | |
| HK1242616B (en) | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |